Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | IL5 | P05113 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521003 | 0.83 | KDM4E (0.49) | KDM4ESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL317285 | 0.83 | CYP1A2 (0.39) | — | |
| SCHEMBL10021099 | 0.80 | KMT2A (0.43) | GRIN2BMETAP1 | |
| SCHEMBL13232174 | 0.80 | EPHX1 (0.47) | GRIN2BACHE | |
| SCHEMBL7904549 | 0.73 | METAP1 (0.34) | METAP1 | |
| SCHEMBL17073447 | 0.73 | RIPK1 (0.53) | GRIN2BKDM4ESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL317788 | 0.73 | DHODH (0.50) | KDM4E | |
| SCHEMBL7897653 | 0.72 | CHRM1 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8336164 | 0.71 | DHODH (0.47) | KDM4ESLC6A3 | |
| SCHEMBL12982580 | 0.70 | RIPK1 (0.35) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | claimed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | claimed |
| EP-2118094-B1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-2257548-B1 | THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-7956051-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2011-06-07 | — | — | US | claimed |
| EP-2247583-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2010-11-10 | — | — | EP | claimed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | claimed |
| WO-2009094286-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2009-07-30 | — | — | WO | claimed |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-07-30 | — | — | US | claimed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2027081-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2285775-B1 | Lactams and their use in the treatment of inter alia ocular hypertension or baldness | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007115020-A2 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | PTGIS, PTGIR, CYP11B2 | GRIN2B 2194/4885METAP1 2470/4885KDM4E 3984/4885 |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | GRIN2B 3420/4885METAP1 2699/4885KDM4E 2381/4885 |
| US-20070259929-A1 | Therapeutic Compounds | PIGO, CYC1, COXFA4L2 | GRIN2B 1865/4885METAP1 1825/4885KDM4E 4030/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | GRIN2B 1930/4885METAP1 2339/4885KDM4E 4189/4885 |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | GRIN2B 1986/4885METAP1 770/4885KDM4E 3697/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | GRIN2B 3420/4885METAP1 2699/4885KDM4E 2381/4885 |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | VIP, SHH, GLI1 | GRIN2B 2607/4885METAP1 4027/4885KDM4E 1468/4885 |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | GRIN2B 2923/4885METAP1 2598/4885KDM4E 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.